Sean David to Treatment Outcome
This is a "connection" page, showing publications Sean David has written about Treatment Outcome.
Connection Strength
0.268
-
Extended treatment for cigarette smoking cessation: a randomized control trial. Addiction. 2017 Aug; 112(8):1451-1459.
Score: 0.058
-
Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend. 2008 Nov 01; 98(1-2):77-85.
Score: 0.031
-
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res. 2007 12; 9(12):1251-7.
Score: 0.030
-
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007 Aug; 9(8):821-33.
Score: 0.029
-
Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J. 2008 Apr; 8(2):122-8.
Score: 0.029
-
The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res. 2007 Feb; 9(2):225-31.
Score: 0.028
-
Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers. Nicotine Tob Res. 2015 Jul; 17(7):855-61.
Score: 0.012
-
Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clin Pharmacol Ther. 2014 Aug; 96(2):256-65.
Score: 0.012
-
Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 2012 Feb; 12(1):86-92.
Score: 0.009
-
Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics. 2010 Mar; 11(3):357-67.
Score: 0.009
-
Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry. 2008 Jun; 65(6):683-93.
Score: 0.008
-
Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1065-9.
Score: 0.007
-
Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob Res. 2004 Oct; 6(5):769-76.
Score: 0.006